These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

947 related articles for article (PubMed ID: 32143329)

  • 1. Liraglutide Protects Against Brain Amyloid-β
    Duarte AI; Candeias E; Alves IN; Mena D; Silva DF; Machado NJ; Campos EJ; Santos MS; Oliveira CR; Moreira PI
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32143329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Niehoff ML; Morley JE; Jelsing J; Pyke C; Knudsen LB; Farr SA; Vrang N
    J Alzheimers Dis; 2015; 46(4):877-88. PubMed ID: 25869785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease.
    Yang JT; Wang ZJ; Cai HY; Yuan L; Hu MM; Wu MN; Qi JS
    Neurosci Bull; 2018 Oct; 34(5):736-746. PubMed ID: 30099679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
    Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
    Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.
    Batista AF; Forny-Germano L; Clarke JR; Lyra E Silva NM; Brito-Moreira J; Boehnke SE; Winterborn A; Coe BC; Lablans A; Vital JF; Marques SA; Martinez AM; Gralle M; Holscher C; Klein WL; Houzel JC; Ferreira ST; Munoz DP; De Felice FG
    J Pathol; 2018 May; 245(1):85-100. PubMed ID: 29435980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model.
    Qi L; Ke L; Liu X; Liao L; Ke S; Liu X; Wang Y; Lin X; Zhou Y; Wu L; Chen Z; Liu L
    Eur J Pharmacol; 2016 Jul; 783():23-32. PubMed ID: 27131827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
    Long-Smith CM; Manning S; McClean PL; Coakley MF; O'Halloran DJ; Holscher C; O'Neill C
    Neuromolecular Med; 2013 Mar; 15(1):102-14. PubMed ID: 23011726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Middle-Aged Diabetic Females and Males Present Distinct Susceptibility to Alzheimer Disease-like Pathology.
    Candeias E; Duarte AI; Sebastião I; Fernandes MA; Plácido AI; Carvalho C; Correia S; Santos RX; Seiça R; Santos MS; Oliveira CR; Moreira PI
    Mol Neurobiol; 2017 Oct; 54(8):6471-6489. PubMed ID: 27730513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
    Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
    Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-23b attenuates tau pathology and inhibits oxidative stress by targeting GnT-III in Alzheimer's disease.
    Pan K; Chen S; Wang Y; Yao W; Gao X
    Neuropharmacology; 2021 Sep; 196():108671. PubMed ID: 34153312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
    Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice.
    Li J; Deng J; Sheng W; Zuo Z
    Pharmacol Biochem Behav; 2012 Jun; 101(4):564-74. PubMed ID: 22425595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble Aβ levels in a triple transgenic mouse model of Alzheimer's disease (3XTg-AD).
    Nakajima A; Aoyama Y; Shin EJ; Nam Y; Kim HC; Nagai T; Yokosuka A; Mimaki Y; Yokoi T; Ohizumi Y; Yamada K
    Behav Brain Res; 2015 Aug; 289():69-77. PubMed ID: 25913833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.
    Li Y; Duffy KB; Ottinger MA; Ray B; Bailey JA; Holloway HW; Tweedie D; Perry T; Mattson MP; Kapogiannis D; Sambamurti K; Lahiri DK; Greig NH
    J Alzheimers Dis; 2010; 19(4):1205-19. PubMed ID: 20308787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"].
    Tamaoka A
    Rinsho Byori; 2013 Nov; 61(11):1060-9. PubMed ID: 24450113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease and amyloid: culprit or coincidence?
    Skaper SD
    Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.